2.94
-0.005(-0.17%)
Currency In USD
| Previous Close | 2.94 |
| Open | 2.95 |
| Day High | 3 |
| Day Low | 2.9 |
| 52-Week High | 4.2 |
| 52-Week Low | 1.33 |
| Volume | 180,910 |
| Average Volume | 742,293 |
| Market Cap | 91.09M |
| PE | -24.46 |
| EPS | -0.12 |
| Moving Average 50 Days | 2.69 |
| Moving Average 200 Days | 2.22 |
| Change | -0.01 |
If you invested $1000 in Fortress Biotech, Inc. (FBIO) 10 years ago, it would be worth $82.21 as of December 14, 2025 at a share price of $2.935. Whereas If you bought $1000 worth of Fortress Biotech, Inc. (FBIO) shares 5 years ago, it would be worth $73.01 as of December 14, 2025 at a share price of $2.935.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout
GlobeNewswire Inc.
Oct 21, 2025 12:30 PM GMT
MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing
GlobeNewswire Inc.
Oct 01, 2025 12:05 PM GMT
Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101
GlobeNewswire Inc.
Oct 01, 2025 12:00 PM GMT
MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a C